| Budget Amount *help |
¥25,220,000 (Direct Cost: ¥19,400,000、Indirect Cost: ¥5,820,000)
Fiscal Year 2020: ¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2019: ¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2018: ¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2017: ¥10,790,000 (Direct Cost: ¥8,300,000、Indirect Cost: ¥2,490,000)
|
|---|
| Outline of Final Research Achievements |
As a result of this research, three candidate factors involved in the early pathophysiology of osteoarthritis have been identified.
First, G protein-coupled receptor kinase 5 (GRK5) was identified as a novel factor that regulates the activation of NFκB in chondrocytes. We are proceeding with a plan to clinically apply the GRK5 inhibitor as a therapeutic drug. Second, we identified DEPP, which is a target gene for FOXO transcription factors and a factor involved in abnormal protein catabolism in cells. The mechanism was mediated by autophagy in mitochondria. Third, a novel kinase involved in the activation of NFκB in osteoarthritis has been identified.
|
